Age years | 69 (65–72) | 67 (61–71)# | 66 (61–71)# | 68 (62–71) |
Male gender | 131 (82) | 185 (76) | 126 (80) | 59 (69)# |
Smokers | 129 (81) (n=159) | 171 (71)# | 116 (74) | 55 (65)# |
Smoking pack-years | 39.0 (15.0–55.0) (n=159) | 30.0 (0.0–50.0)# | 30.0 (0.0–51.0) | 30.0 (0.0–46.5)# |
FVC L | 2.40 (1.85–2.93) | 2.73 (2.01–3.27)# | 2.78 (2.07–3.28)# | 2.60 (2.04–3.29) |
FVC % predicted | 74.0 (63.8–89.4) | 88.3 (72.8–100.4)# | 87.4 (72.8–99.9)# | 89.2 (72.7–102.2)# |
DLCO % predicted | 52.8 (41.0–66.6) (n=155) | 65.6 (52.4–82.9)# (n=238) | 63.1 (51.7–79.3)# (n=155) | 69.6 (55.9–87.3)# (n=83) |
PaO2 mmHg | 78.0 (70.8–87.7) (n=155) | 82.3 (74.7–90.7)# (n=230) | 82.0 (76.0–91.4)# (n=154) | 82.4 (73.4–89.2) (n=76) |
Treatment | | | | |
Anti-fibrotics | 87 (54) | 115 (48) | 92 (59) | 23 (27)#,¶ |
Corticosteroids | 18 (11) | 41 (17) | 24 (15)# | 17 (20)# |
Histopathological pattern | n=32 | n=109 | n=72 | n=37 |
Definite/probable UIP | 27 (84) | 90 (83) | 71 (99) | 19 (51)+ |
Indeterminate for UIP | 2 (6) | 5 (5) | 1 (1) | 4 (11) |
Alternative diagnosis | 3 (9) | 14 (13) | 0 (0) | 14 (38) |
Final diagnosis (with SLB) | | | | |
IPF | 26 (81) | 72 (66) | 72 (100) | 0 (0) |
NSIP | 1 (3) | 8 (7) | 0 (0) | 8 (22) |
Unclassifiable ILD | 4 (13) | 22 (20) | 0 (0) | 22 (59) |
Other | 1 (3) | 7 (19) | 0 (0) | 7 (19) |
Final diagnosis (with clinical diagnosis) | | | | |
IPF | 154 (96) | 157 (65) | 157 (100) | 0 (0) |
NSIP | 1 (1) | 8 (3) | 0 (0) | 8 (9) |
Unclassifiable ILD | 4 (3) | 70 (29) | 0 (0) | 70 (82) |
Other | 1 (1) | 7 (3) | 0 (0) | 7 (8) |